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Available online 13 April 2016Cancer constitutes a set of diseases with heterogeneous molecular pathologies. However, there are a number of
universal aberrations common to all cancers, one of these being the epigenetic silencing of tumor suppressor
genes (TSGs). The silencing of TSGs is thought to be an early, driving event in the oncogenic process. With this
in consideration, great efforts have been made to develop small molecules aimed at the restoration of TSGs in
order to limit tumor cell proliferation and survival. However, themolecular forces that drive the broad epigenetic
reprogramming and transcriptional repression of these genes remain ill-deﬁned. Undoubtedly, understanding
the molecular underpinnings of transcriptionally silenced TSGs will aid us in our ability to reactivate these key
anti-cancer targets. Here, we describe what we consider to be the ﬁve most logical molecular mechanisms that
may account for thiswidely observed phenomenon: 1) ablation of transcription factor binding, 2) overexpression
of DNAmethyltransferases, 3) disruption of CTCF binding, 4) elevation of EZH2 activity, 5) aberrant expression of
long non-coding RNAs. The strengths and weaknesses of each proposed mechanism is highlighted, followed by
an overview of clinical efforts to target these processes.
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TSGs code for proteins that restrict the proliferative and survival ca-
pacity of a cell. Such genesmay be rendered dysfunctional throughmul-
tiple mechanisms during the oncogenic process. These include
mutation, deletion, genetic rearrangement, and epigenetic silencing of
transcription. Some TSGs, such as the classic tumor suppressor TP53,
are primarily inactivated through mutation. In contrast, other tumorthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Schematic highlighting ﬁve potential mechanisms utilized during the oncogenic
process to silence tumor suppressor genes: 1. overexpression of DNA methyltransferases;
2. overexpression of EZH2; 3. dissociation of CTCF from chromatin boundaries; 4. loss of
transcription factor binding; 5. aberrant expression of long non-coding RNAs. Green circles
represent “activating” epigenetic marks such as histone acetylation, or H3K4me3. Red
circles represent repressive histone modiﬁcations such as H3K27me3 or H3k9me3. Gray
circles represent DNA methylation.
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tion, deletion, or epigenetic silencing. The motivation for cancer cells
to challenge the function of some TSGs through multiple mechanisms,
while others primarily through a single means, remains unclear. Per-
haps this is dependent on the need for a tumor suppressor protein to
be expressed for survival, even if it ismutated, rendering it only partially
dysfunctional. Alternatively, the position of a gene within the nucleus
maydictate themolecular forces inﬂuencing themechanismof inactiva-
tion. While environmental carcinogens may inﬂict mutations in TSGs,
the molecular mechanisms whereby gene deletions, rearrangements
and epigenetic silencing are initiated is less obvious. It should be
noted that there is wide recognition that environmental carcinogens
promote the silencing of tumor suppressor genes [1,2], but the mecha-
nism delineating precisely how the external environment communi-
cates with the nucleus to propagate silencing of TSGs requires further
work.
An important aspect of TSG silencing that is often overlooked is that
the process leading to transcriptional shutdown does not rely on a sin-
gle epigenetic event. Epigenetic silencing is associated with a dynamic
reprogramming of the epigenetic code primarily in the promoter region
of affected genes. This reprogramming is associated with a loss of acti-
vating histonemarks (e.g. H3K4me3 andH3K9ac), a loss of histone var-
iants (e.g. H2A.Z), a loss of DNAse I hypersensitive sites, and a gain of
several key repressive histone marks (e.g. H3K9me3, H3K27me3),
alongwith hypermethylation of promoter DNA. Thus, amodel outlining
prospective mechanisms for TSG silencing should, in theory, be able to
explain the plethora of changes observed in these regions. Beyond the
promoter, DNA methylation is commonly lost from intergenic regions,
and much of the genome is hypomethylated. Through understanding
the precise mechanism whereby TSG silencing is initiated and main-
tained, we will undoubtedly identify new targets for anti-cancer thera-
py. By drugging the epigenetic processes that establish TSG silencing,
wemight reverse this process as ameans to block the growth of primary
tumors, or even impede epigenetic silencing before it happens as a
means of cancer prevention.
Is the avoidance of TSG silencing really a target for cancer preven-
tion? Evidence suggests that TSG silencing is an early, initiating event
in the oncogenic process, and therefore, maintaining expression of
these genes may well impede the onset of tumorigenesis. For example,
CDKN2Awas found to be silenced in the mammary tissue of women at
high risk for breast cancer, highlighting the early nature of this oncogen-
ic lesion [3]. Consistent with this, a premalignant zone surrounding a
primary breast tumor has been described wherein TSGs are found in a
silenced state [4,5]. In addition to the insight regarding tumor initiation,
these studies indicate that the tissue surrounding a primary tumor,
often characterized as “normal tissue,” is in fact not normal at all. Nota-
bly, after surgery and therapy, breast tumor recurrence is commonly ob-
served within a zone proximal to the primary site. It is possible that this
premalignant zone encounters further genetic hits (or is genetically un-
stable), after removal of the primary tumor, accounting for the proximal
recurrence. Regardless, these data indicate that intervention aimed at
protecting cells from epigenetic silencing of TSGs is a rational means
to prevent cancer initiation.
Not only has the silencing of TSGs been correlated with tumor initi-
ation, but with oncogenic progression as well. For example, in melano-
ma, DNA methylation of a panel of commonly silenced TSGs, including
RASSF1A and GATA4 among others, predicts advanced clinical staging
and metastasis [6]. Other reports show a similar association between
the epigenetic silencing of CDH1 and melanoma progression [7]. These
and many other reports indicate reactivating tumor suppressor genes
represents a reasonable approach to anti-cancer therapy.
Because TSGs undergo epigenetic silencing in practically all cancers,
it is hoped that understanding the molecular mechanisms contributing
to transcriptional silencingwill also highlight new therapeutic targets to
treat a spectrum of malignancies. While this lofty goal has yet to be re-
alized, to date, this theory has been shown to hold some merit, withboth DNA methylation and histone deacetylation inhibitors being FDA
approved to treat hematopoietic malignancies. There is also strong pre-
clinical data indicating that inhibitors of the chromatin modifying pro-
teins Ezh2 and Brd4 will have some clinical applicability. Drugging the
epigenome will be discussed in more detail below.
In this review, we will focus on understanding the mechanisms
whereby tumor suppressor gene silencingmight be initiated andmain-
tained in cancer cells, highlighting the strengths and shortcomings of
each theory. While there may be additional mechanisms than the
ones proposed, we cover those models which are both logical, and sup-
ported by substantial experimental data. Five models are proposed
(Fig. 1): 1) defects in the transcriptional process, 2) overexpression of
DNA methyltransferases, 3) dysfunction of CTCF, 4) overexpression of
the polycomb protein Ezh2, and 5) aberrant expression of long non-
coding RNAs. Overall, we think it is likely that these mechanisms work
in concert to initiate, and maintain, the epigenetic silencing of TSGs.
2. Defects in the transcriptional process
Defects in the transcriptional processmay be themost obvious cause
of transcriptional silencing, but it is also themost overlooked.We deﬁne
“defects in the transcriptional process” as molecular perturbations to
trans-activating factors, or the core transcription machinery, that im-
pinges on the capacity of RNA Polymerase II (Pol II) to transcribe a target
gene. At ﬁrst glance, there may seem to be a disconnection between the
suppression of gene transcription and the acquirement of repressive
epigenetic marks, but evidence exists suggesting that this is not the
case, and in fact, the two may be tightly linked.
Genome-wide mapping of DNA methylation patterns in Arabidopsis
reveals active transcription may shape the DNA methylation landscape
[8]. Supporting this study, classicwork from the Cedar and Bird research
groups using transgenic mouse models both show that mutation of SP1
binding sites leads to a localized accumulation of DNA methylation [9,
10].
Beyond SP1, other transcription factors have been demonstrated to
limit the accumulation of DNA methylation at target genes in multiple
types of tissues. Examples of these include the neuronal factor NGFI-A
[11], REST, CTCF, or RFX family members in embryonic stem cells [12,
13]. Importantly, this paradigm seems to have relevance at distal regu-
latory regions across the genome, where transcription factor occupancy
maintains regions of low-density DNA methylation [14]. This interplay
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be quite complex. For example, it has been shown that de novomethyl-
ation outcompetes NRF1 binding and that the NRF1 site itself does not
act as a shield against localized DNA methylation [15]. But deletion of
NRF1 ﬂanking sites for factors including CTCF, or RFX, does lead to a sig-
niﬁcant gain of DNAmethylation indicating transcription factors act as a
barrier against the activity of DNAmethyltransferases (DNMT). It is also
possible that the transcriptional activity of Pol II itself may act as an im-
portant means to restrict DNAmethylation. One of the shortcomings of
these studies is that the relationship between transcription factor bind-
ing and Pol II recruitment is often not clearly delineated. One scenario
not accounted for by these studies is that the loss of transcription factors
critically involved in Pol II recruitment will result in subsequent DNMT
recruitment because of the loss of Pol II itself. In contrast, the loss of fac-
tors acting on other steps of transcription, such as elongation,would not
result in increased DNA methylation.
Recently, a seminal paper from the Heinlein lab revealed that phar-
macological blocking of Pol II mediated transcription with DRB (5,6-
dichloro-1-beta-D-ribofuranosylbenzimidazole) leads to an accumula-
tion of the repressive histonemodiﬁcation H3K27me3 [16]. This ﬁnding
suggests that active transcription may be required to prevent the accu-
mulation of marks that promote and maintain epigenetic silencing. The
accumulation of other classic modiﬁcations associatedwith heterochro-
matin such as DNA methylation, and H3K9me3, were not probed for in
this setting. Nonetheless, these data raise the interesting possibility that
the loss of transcription factor binding to target genes, resulting in inac-
tivation of transcription, may, in turn, promote the accumulation of re-
pressive histone modiﬁcations.
A question arising from this body of work is, “What are the molecu-
lar defects that compromise transcription factor binding in cancer”? Ob-
viously, mutation can impact protein–DNA associations, but are there
other driving forces? Transcription factor binding is intricately linked
to signaling cascades from receptor tyrosine kinases (RTKs). Hyper-
activation of such signaling pathways is a driving force in many malig-
nancies. Intriguingly, activation of oncogenic drivers such as KRAS or
HER2 are associated with precise patterns of DNA methylation
[17–19]. While the mechanism for this association remains ambiguous,
it is possible that constitutive activation of signaling cascades disturbs
transcription factor binding in a predictable fashion, leading to deﬁned
patterns of altered DNA methylation. As an alternative explanation,
these oncogenic drivers may also inﬂuence the other mechanisms of si-
lencing we describe below.
Our conclusion from these studies is that the loss of transcription
factor binding represents a rational yet understudied mechanism
whereby the expression of tumor suppressor genes may be lost in can-
cer. One envisions that the loss of a transcription factor critical for the
trans-activation of multiple TSGs could reasonably result in the concur-
rent epigenetic deregulation that is observed in so many tumors. It
would be interesting to carry out ChIP-seq proﬁling of tumors to assess
whether loss of transcription factor binding is indeed associated with
transcriptional silencing. Further, it is clear that more work needs to
be done using pharmacological inhibition of Pol II with such agents as
ﬂavopyridol and α-amanitin, coupled with knockdown experiments
andmutation of transcription factor binding sites, to establish that tran-
scription is truly antagonistic to the accumulation of repressive epige-
netic marks.
3. Initiation and maintenance of epigenetic silencing by DNA
methyltransferases
Eukaryotic DNA is commonly methylated on the 5th atom of cyto-
sines residues in the dinucleotide sequence CpG. In vertebrates, DNA
methylation is mainly mediated by three enzymes: DNMT1, DNMT3a,
andDNMT3b. DNMT1 is referred to as amaintenance DNAmethyltrans-
ferase. The strong afﬁnity of DNMT1 for hemimethylated DNA, and in-
teraction with PCNA, ensures that daughter strands obtain a correctDNA methylation proﬁle during replication. DNMT3a/b principally act
as de novo methyltransferases, and it is these family members which
are thought to play a major role in mediating the epigenetic silencing
of tumor suppressor genes in cancer.
Across the majority of the genome, CpG sites are underrepresented
and heavily methylated. In contrast, there are at least two discrete re-
gions of the genome where low-density DNA methylation is found.
The ﬁrst, called “CpG islands,” are loci deﬁned by an enrichment for
CpG dinucleotides at much higher frequency than found randomly
throughout the vast majority of the genome. These islands are usually
associated with gene promoters and are distributed in a non-random
manner to generate a pattern of DNA methylation that is site-, tissue-,
and gene-speciﬁc. CpG island DNA methylation is strongly associated
with transcriptional silencing and maintenance of CpG islands in an
unmethylated state is important for gene activity. Promoter DNAmeth-
ylation is generally considered to be the culminating step in the silenc-
ing process, with repressive histone modiﬁcation facilitating
subsequent DNAmethylation, resulting in long-term, often irreversible,
shutdown of transcription [20,21].
In addition to CpG-rich promoters, enhancer regions also represent a
region of low-density DNA methylation [22]. Enhancers are key tran-
scriptional elements ensuring proper tissue-speciﬁc gene expression.
Hypomethylated enhancers allow trans-activating factors to bind and
promote transcriptional elongation of corresponding target genes.
The normal pattern of genomic DNA methylation is dramatically al-
tered during neoplastic transformation. There is a reversal of this meth-
ylation acrossmuchof the genome fromaheavilymethylated landscape
to a hypomethylated state especially at intergenic regions [23–25]. It
has been proposed that decreased DNA methylation in repeat se-
quences promotes genomic instability such as chromosomic deletions
and translocations [26–28]. Conversely, an aberrant gain of DNA
methylaton at the CpG islands and enhancer regions of critical tumor
suppressor is observed in most, if not all, cancers. For example, the pro-
moter DNA of some key tumor suppressors, such as CDKN2A and
RASSF1a, controlling cell cycle and apoptosis, is hypermethylated in a
broad spectrum of cancers and premalignant tissues. However, a gain
of DNAmethylation at enhancersmay be amore signiﬁcantmechanism
of gene silencing in cancer than the hypermethylation of promoter DNA
[29,30].
Cancer cell lines were ﬁrst shown to harbor highly elevated DNA
methyltransferase activity relative to normal cells in the 1980s by the
group of Peter Jones [31]. In another landmark paper, the same group
later demonstrated overexpression of DNMT3b in tumors [32]. Many
other reports have substantiated these ﬁndings in multiple cancers
[33,34]. Clearly, there is a selective pressure to up-regulate DNAmethyl-
transferase activity in cancer cells, andDNMT3b up-regulation in partic-
ular promotes tumor progression in murine colorectal models through
silencing SRFP tumor suppressors [35]. Moreover, DNA methylation
may affect oncogenic progression not only by acting on gene expression
but also by increasing the mutation rate of methylated cytosines, com-
pared to unmethylated residues [36]. But is DNMT3a/b overexpression
necessary or sufﬁcient for the silencing of most tumor suppressor
genes? Alternatively, do DNMTs work in concert with the other mecha-
nisms proposed herein to induce gene silencing?
There is much evidence that DNMT expressionmaintains epigenetic
silencing of key TSGs [37–40]. For example, knockdown of DNMT1 in
tandem with DNMT3b reactivates one of the most common epigeneti-
cally silenced genes, CDKN2A [39]. The initiation of silencing can be con-
sidered a separate event from maintenance. It has not been ﬁrmly
established that simple overexpression of DNMTs can initiate the silenc-
ing of TSGs, but there is at least some evidence supporting such a role
[41]. For example, using a transgenic mouse model of colorectal cancer,
it was demonstrated that overexpression of DNMT3b leads to changes
in gene proﬁling congruent to what is observed in human colorectal
cancer [42]. However, overall, there is a lack of direct evidence that sim-
ple overexpression of DNMTs initiates gene silencing in cancer. It is
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factors, includingH3K9me3modiﬁcation, or via binding to transcription
factors. Independent model systems predict epigenetic modiﬁcation of
histones with repressive marks, especially H3K9me3, precedes DNA
methylation [21,43]. There is even evidence in vitro that cells pressured
to transform through ectopic overexpression of DNMT3b will ﬁrst turn
off transcription of key tumor suppressors through acquirement of re-
pressive covalent histone modiﬁcations (H3K9me2 and H3K27me3)
prior to acquisition of DNA methylation [2].
In addition to epigenetic marks, DNMTs may be recruited to target
genes via interactions with a variety of transcription factors [44]. PU.1
and MYC, in particular, represent examples of transcription factors
that may aberrantly target DNMT3b to the promoters of classic tumor
suppressor genes leading to gene silencing [45,46]. The idea that re-
cruitment to promoter regions initiates silencing is supported by a re-
cent paper showing that DNA methyltransferase activity targeted to
theCDKN2Apromoter using engineered zincﬁngers, results in complete
silencing of the gene [47]. Interestingly, genome-wide surveys of DNMT
localization ﬁnd that DNMTs are commonly found at actively tran-
scribed loci [48]. Based on these data, it was postulated that disruption
of chromatin boundaries (also described herein) may broaden the
DNA territory targeted by DNAmethyltransferases, leading to promoter
silencing [48]. Supporting this concept, chromatin boundaries them-
selves may act as focal points to recruit PARP1, whose enzymatic action
has been shown to suppress DNMT1methyltransferase activity [49,50].
In general, tumor suppressors are epigenetically silenced in a higher
percentage of tumors than those showing aberrant DNMT overexpres-
sion, necessitating additional mechanisms of silencing. Clinically, if
DNMTs are initiating down-regulation of tumor suppressor gene tran-
scription, one would expect to see a strong correlation between high
DNMT expression and shutdown of TSGs. However, this link has been
wildly variable. Theﬁrst study to explore the relationship focused on co-
lorectal cancer and failed to see a relationship between DNMT3a/b ex-
pression and DNA methylation of APC, ESR1, p16, or MLH1 promoters
[51]. Similar absences of such a correlation has been reported for can-
cers of the breast [34,52], lung [53–55], prostate [56], liver [57], stomach
[58], andmyelodysplasia [59]. In stark contrast, conﬂicting reports claim
there is indeed a correlation between high DNMT levels and hyperme-
thylation of TSGs, in many of the same tumors listed above [60–64]. It
is difﬁcult to draw conclusions from such divergent studies. Most of
these clinical studies merely examined a small subset of genes found
hypermethylated in each individual cancer. If larger cohorts of methyl-
ated promoters were examined, then stronger correlations might be
identiﬁed.
Mechanistically, DNMT overexpression is likely to play an important
role in the concurrent silencing of many tumor suppressor genes. Still,
key questions remain. In tumors where DNMTs are not highly
expressed, what mechanisms can explain the silencing? Is aberrant
transcription factor binding necessary to recruit DNMT3b to TSGs?
Large stretches of the genome become hypomethylated during tumori-
genesis and hyperactive DNAmethyltransferase activity cannot account
for this phenotype in an obvious manner. We now proceed to explore
other mechanisms of silencing that may work in concert with, or in
lieu of, DNMT overexpression.4. Loss of CTCF binding disrupts epigenetic boundaries
Epigenetic silencing of tumor suppressor genes is not an isolated
event. Within any given tumor, several, if not many, TSGs are transcrip-
tionally silent. Even within hyperplasia, or normal tissue of patients at
high risk for cancer, multiple genes regulating proliferation or survival
can be found shut down. While TSGs are often concurrently silenced,
it is unclear if shared, or independent mechanisms are in place to
coregulate these genes. If these genes were indeed coregulated, a single
genetic aberration might explain their concurrent silencing. One suchexplanation could reside in coregulation by the epigenetic regulatory
protein CTCF.
CTCF was ﬁrst described as a transcriptional repressor of the MYC
gene, but subsequent knockdown studies reveal CTCF primarily plays
a role in gene activation [65,66]. CTCF may impact gene expression at
multiple levels including modulating Pol II activity directly, or via orga-
nization of tertiary chromatin structure. CTCF interacts with several
transcription factors and even components of Pol II itself [67–69].
Thus, CTCF may inﬂuence transcription directly via recruitment of Pol
II subunits or by promoting transcriptional initiation.
Elegant genome-wide chromosomal interaction studies have re-
vealed a complex role for CTCF in mediating inter- and intra-
chromosomal attachments. The anchor points for these attachments
have now been shown to be enriched for Pol II occupancy, consistent
with the reports outlined above suggesting an interplay between CTCF
and Pol II activity [70,71]. CTCF facilitates such long-range cis and trans
interactions through the formation of homodimers, bringing multiple
CTCF sites in contact with one another, or alternatively, in collaboration
with the cohesin complex. Connections in cis result in chromatin
looping, with shorter loops being assembled within large loops [72].
The orientation of the CTCF-binding sites anchoring chromatin loops
strongly inﬂuences their assembly, with the majority of CTCF anchor
sites oriented in a convergent fashion [70,73]. While more functional
studies are warranted, there is evidence that chromatin loops mediated
by tandemly arranged CTCF sites may coordinate promoter-enhancer
interactions [73].
The largest of these loops deﬁne chromatin domains, within which,
cis connections aremade, but not to sites outside this topologically asso-
ciating domain (TAD) [72]. The CTCF-binding at the 5′ and 3′ limits of
these TADs can act as an insulator, preventing aberrant connections be-
tween adjacent TADs. Not only do these boundaries act as insulators, but
they are also able to act as classical “chromatin boundaries,” partitioning
distinct epigenetic domains [74]. Historically, these boundaries are
thought to prevent the spread of heterochromatin, which is considered
to be the “default state” [75–77]. There is a considerable body of work
supporting a role for CTCF in maintaining chromatin boundaries in
order to prevent the spread of repressive heterochromatin [78–81].
One compelling example is provided by the group of Recillas-Targa,
who show that a CTCF boundary constrains the spread of heterochro-
matin at the FOLR1 gene [82]. During the course of erythroid differenti-
ation, CTCF binding is displaced, with a concomitant spread of
repressive chromatin (DNAse I resistant) and gene repression ensuing.
A recent seminal discovery from the Reinberg research group muddies
this paradigm [83]. Therein, they clearly demonstrate, via genome
editing, that the loss of a CTCF boundary actually leads to aberrant
spreading of histonemodiﬁcations associatedwith euchromatin and ac-
tively transcribed genes.
Functional studies of long-range chromatin connections are in its in-
fancy and many key questions are yet to be answered. Future studies
will need to examine whether CTCF protein involved in mediating
these interactions also plays an active role in regulating nearby genes,
or recruits histone-modifying enzymes. It is also unclear precisely how
boundaries prohibit the spread of histone modiﬁcations. Mutation of
CTCF sites in vivo and in vitro results in local accumulation of DNA
methylation [84,85], but it is unclear if this is associated with disruption
of long-range interactions. Not all CTCF sitesmediate long-range associ-
ations, indicating CTCF truly is a multifunctional protein with roles be-
yond establishing DNA interaction in cis and trans.
CTCF binding is observed throughout the genome but may become
disassociated from key sites in cancer cells [86–91] (Table 1). This loss
of binding has yet to be conﬁrmed directly from tumor samples. Disrup-
tion of CTCF binding has been correlatedwith down-regulation of tumor
suppressor genes and aberrant accumulation of repressive histonemod-
iﬁcation and DNA methylation. It is thought that the lack of CTCF bind-
ing releases repressive chromatin modiﬁcation from the constraints
imposed by chromatin boundaries, allowing them to spread passively
Table 1
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their transcription. Related to this idea, it has also been demonstrated
that CTCF is important for maintaining DNA methylation-free regions
[86]. It is possible that CTCF boundaries act as focal points for PARP1 re-
cruitment, and it is actually the localized accumulation of poly(ADP-ri-
bose) polymers that prohibits DNMT1 methyltransferase activity in
these regions of the genome [49,92].
Lamina-associated domains (LADs) are repressive chromatin do-
mains tethering chromosomes to the nuclear periphery. Independent
reports indicate the massive domains of DNA hypomethylation found
in cancer are enriched at LADs [24,93]. Notably, LADs are generally insu-
lated by CTCF [94,95]. Taken together, it is tempting to speculate that
disruption of CTCF binding reorganizes LADs and the spatial distribution
of chromatin within the nucleus, leading to aberrant patterns of DNA
methylation.
CTCFmay also be related to genome-wideDNAmethylation patterns
through interplaywith the histone variant H2A.Z [96]. CTCF positions an
array of 20 nucleosomes around each binding site, with the array being
enriched for the histone variant H2A.Z. In Arabidopsis, and Puffer ﬁsh,
H2A.Z placement is anti-correlated with DNA methylation [97,98] and
loss of proper H2A.Z positioning results in genome-wide accumulation
of DNA methylation [97]. This is consistent with mammalian data indi-
catingH2A.Z is often enriched at euchromatic regions of the genome, es-
pecially promoter and enhancer regions [99]. Notably, knockdown of
CTCF by shRNA, RNAi, or conditional knockout leads to loss of H2A.Z in-
corporation at CTCF regulated genes [88,100]. Thus, we might extrapo-
late that displacement of CTCF from cognate binding sites leads to a
loss of H2A.Z and destabilization of chromatin boundaries, culminating
in a deregulated accumulation of DNA methylation.
CTCF binding to a subset of DNA elements is known to be disrupted
by DNA methylation of CpGmotifs found within its cognate DNA-bind-
ing element [101]. This leads to a “chicken and egg” scenario where it is
unclearwhether loss of CTCF is the initial event, leading to accumulation
of proximal DNA methylation, or alternatively, whether spurious DNA
methylation events displace CTCF, which would indicate a role in the
maintenance of silencing, rather than initiation. There are data
supporting a direct, or causal, role for CTCF in opposing the accumula-
tion of repressive epigenetic marks. Elegant in vitro and in vivo studies
demonstrate that disruption of CTCF-binding sites within cells, such
that the protein can no longer bind, will indeed lead to the localized ac-
cumulation of repressive epigenetic marks including DNA methylation
[78,84,85,102]. These studies have been complemented with work
using CTCF knockdown leading to similar conclusions [87,100].
How is CTCF binding disrupted in cancer? There are at least ﬁve pos-
sible mechanisms, and perhapsmore to be discovered. First, CTCF-bind-
ing sites can be found mutated, prohibiting CTCF binding [91]. Second,
CTCF itself is mutated in a spectrum of cancers, notably at 18% or higher
in endometrial cancers [103]. Overall, the impact of these mutations on
CTCF function is awaiting clariﬁcation, but several of the mutations
identiﬁed within the DNA binding domain disrupt its binding to thepromoters of several tumor suppressor genes in vitro [104]. Third, loss
of the post-translational modiﬁcation poly(ADP-ribosylation) from
CTCF has been detailed in breast tumors [105]. In Drosophila, such a
loss of poly(ADP-ribosylation) results in a release of a fraction of total
CTCF from chromatin [106]. Fourth, the association of CTCF with non-
coding RNAs is important for its organization into multimers [107].
CTCF homodimers are important for establishing intra-chromosomal
contacts and chromatin boundaries. Thus, the dissociation of CTCF
from these RNAs, either through mutation or other means, could very
well lead to a disruption of chromatin boundaries and gene silencing. Fi-
nally, there is evidence that CTCF may be targeted to a subset of pro-
moters by protein cofactors [68,69]. Disruption of such an interaction,
while not described in tumors, would lead to ablation of CTCF binding
at these target genes.
Within tumors, TSGs are not silenced as solo events, but multiple si-
lencing events are often concurrent. Similarly, aberrant epigenetic
changes at these genes are not conﬁned to a single modiﬁcation, but a
reversal of an entire spectrum of modiﬁcations is observed. The disrup-
tion of a single CTCF site can, in fact, explain both of these phenomena in
perhaps a more satisfying manner than other proposed mechanisms of
silencing. As outlined above, CTCFmediates long-range chromatin inter-
actions, including those between non-homologous chromosomes.
Therefore, in theory, the loss of a single CTCF site could impede the tran-
scription on neighboring chromosomes, resulting in a network of silenc-
ing that could even trigger a chain event of silencing. Further, ablation of
a chromatin boundary maintained by CTCF will result in the passive
spread of epigenetic modiﬁcations found ﬂanking the boundary [71].
One envisions that a wave of heterochromatin might encroach upon
tumor suppressor genes if proximal boundaries were compromised.
A major weakness of the CTCF hypothesis is the lack of clinical vali-
dation. It remains to be seen whether CTCF binding is really lost from
epigenetically silenced genes in tumor samples, or if this is simply an ar-
tifact of tissue culture. Future ChIP analysis of frozen tumor specimens
will be key for validation. Finally, CRISP/Cas9 manipulation of CTCF
binding sites is needed to assess the notion of concurrent silencing,
and whether loss of individual CTCF sites near tumor suppressors does
indeed disrupt boundaries leading to a spread of heterochromatin
marks.
5. Transcriptional repression by EZH2 overexpression
Members of the polycomb group (PcG) genes were identiﬁed
60 years ago in Drosophila melanogaster as regulators of Hox gene clus-
ters. Because mutation of PcG proteins resulted in activation of Hox
gene expression, PcG were accurately classiﬁed as repressors [108].
PcG proteins are organized into two complementary complexes.
Polycomb repressive complex 1 (PRC1) and PRC2. PRC2 has protein
methyltransferase catalytic activity mediated by the EZH2 subunit
[109]. EZH2 covalently modiﬁes Histone 3 on lysine 27, placing a tri-
methylated tag (H3K27me3) that negatively impacts transcription
[110]. H3K27me3 is in turn recognized primarily by the CBX2 subunit
of the PRC1 complex [110]. Once recruited to promoters via
H3K27me3, the PRC1 complex represses transcription by prohibiting
Pol II occupancy [111], possibly through occlusion of key members of
the preinitiation complex [112]. Notably, PRC1 is now known to be re-
cruited to genes via association with non-coding RNAs (reviewed
below).
EZH2 has been clearly demonstrated to possess oncogenic proper-
ties [113], is commonly overexpressed in a variety of malignancies,
and has been correlated with poor overall survival. Supporting its role
as an oncogene, somatic, activating EZH2 mutations are thought to be
an oncogenic driver of DLBCL. Under physiological conditions, EZH2 is
a key regulator of many TSGs found silenced in cancer [114], and it is
generally understood that EZH2 promotes oncogenic progression
through the silencing of tumor suppressor genes [115]. Interestingly,
there are data indicating TSGs targeted for epigenetic silencing in cancer
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down [114,116,117]. Thus, during the oncogenic process, this mark
somehow predisposes genes for further repressive programming.
Knockdown of EZH2 revealed that it plays an important role in prolifer-
ation, speciﬁcally through advancement of the cell cycle. However, it is
possible that EZH2harbors oncogenic functions beyond its ability to cat-
alyze the transfer ofmethyl groups onto histones [118]. Therefore, EZH2
may control cell cycle progression via mechanisms independent of its
capacity to silence TSGs.
As mentioned above, the promoters of TSGs epigenetically silenced
invariably display enrichment for H3K27me3. But is this mark an initia-
tor of silencing, important for maintenance of long-term silencing, or
does it somehow aberrantly target these genes for DNA methylation
speciﬁcally in cancer cells? Regarding the mechanism of initiation,
there is indeed evidence that EZH2 represents an important piece of
this puzzle. We know that epigenetic silencing is an early event during
oncogenesis. Two reportsﬁndEZH2overexpression in premalignant tis-
sue of the lung [119] and breast [120], consistent with EZH2 playing a
key role in such silencing. EZH2 has also been shown to directly repress
the expression of classic tumor suppressor genes such as CDKN2A [121]
and RARβ [122] (for a list of targets, see Table 2). It is unclear how over-
expression of EZH2 results in precise targeting of the PRC2 complex to
transcriptionally active promoters. Further, it is unclear that ectopic ex-
pression of EZH2 leads to an accumulation of repressive epigenetic
marks such as H3K9me3 and DNA methylation that are observed at
TSGs within tumors.
If EZH2 plays a role in the maintenance of epigenetic silencing, then
knockdown of EZH2might be expected to restore the expression of tar-
gets, and there should be a correlation between elevated EZH2 and DNA
hypermethylation of TSGs. Knockdown, or pharmacological inhibition
of EZH2, does increase the expression of TSGs such as CDKN2A and
CDKN1A [117,123], but it is unclear that loss of EZH2 activity will reacti-
vate genes whose promoters are enriched for DNA methylation [124,
125]. Even if knockdown of EZH2 cannot overcome the epigenetic lock
set in place by DNA methylation, it is possible that EZH2 contributes
to the initiation of silencing, leading to the further epigenetic
reprogramming that is commonly observed at silenced tumor suppres-
sor genes, culminating in DNA methylation. It is clear that targetingTable 2
Known EZH2 target genes.
Gene Cell type
CDKN1A, TP53, PTEN B-cell acute lympbhoblastic
leukemia
CDKN2A Multiple cancers, normal tissue
CDKN2B Acute myeloid leukemia







NKD1, PPP2R2B, PRICKLE1, SFRP5 Hepatocellular carcinoma
CDKN1C Breast cancer
CAS11 Neuroblastoma
CLU, AML2, TNFRSF16 Neuroblastoma
TSSC3 Osteosarcoma
MiR-302a, miR-4448 Gastric and liver cancers
CDKN1A, CDKN1B Diffuse large B-cell lymphoma
ARHI Ovarian cancer









AF9Q34 Medulloblastomapolycomb proteins to the promoters of tumor suppressor genes, such
as Rassf1a, does indeed lead to transcriptional repression [126], but
does this lead to subsequent reprogramming [127]? The relationship
between PcG target genes and DNA methylation is complex and more
study is needed before it is completely understood. Certainly, in stem
cells, bivalent domains are well characterized, with regions of
H3K27me3 and H3K4me3 coexisting without further accumulation of
repressive marks. Similarly, in AML blasts, H3K27me3, as well as
EZH2, is seen to extend throughout the INK4a (comprising CDKN2A
and CDKN2B genes) locus irrespective of the DNA methylation status
of the gene [128]. At silenced TSGs in cancer cells, H3K27me3 and
DNA methylation invariably co-occur. There is indication that the
CBX7 subunit of PRC1 may bind and recruit DNMT1 or DNMT3b [129].
Is it possible that overexpression of speciﬁc PcG subunits in cancer
leads to aberrant recruitment of DNMTs to TSGs in cancer cells?
Clinically, it is ﬁrmly established that EZH2 is oncogenic and corre-
sponds with disease progression in a number of cancers [130,131].
However, it is unclear that a strong correlation exists between EZH2
overexpression and the silencing of TSGs, but EZH2-mediated silencing
may be through tissue-speciﬁc mechanisms [56,128,132–136]. Consis-
tent with the idea of tissue-speciﬁc effect on gene silencing, TCGA data
indicate EZH2 levels are inversely linked to the repression of a GSTP1,
RARB, and TIMP3 in prostate cancer, but this is not observed within
breast tumors (Fig. 2). As is the case with DNMTs, most studies attempt
to draw correlations between EZH2 overexpression and the DNAhyper-
methylation and silencing of only a small number of handpicked genes.
Genome-wide proﬁling will be necessary to draw stronger correlations.
An interesting development in the ﬁeld of EZH2 biology is the ﬁnd-
ing that PcG proteins work in a coordinated fashion with non-coding
RNAs to silence target genes. This concept helps ﬁll an important gap
in our knowledge regarding the recruitment of polycomb complexes
to speciﬁc loci.6. Non-coding RNAs
Non-coding RNAs have ﬁrmly established themselves as major
players in the ﬁeld of cancer biology. Until recently, the spotlight has
been primarily on the role of small RNAs (microRNAs (miRNA), endog-
enous small interfering RNAs (siRNAs), and PIWI-associated RNAs
(piRNAs)) in cancer. Recently, however, the long non-coding RNAs
(lncRNAs) have received considerable recognition for their contribution
towardmultiple aspects of tumor growth and cancer progression [137].Fig. 2. Inverse correlation between EZH2 expression and the repression of tumor
suppressor genes is tissue-speciﬁc. Expression data from “The Cancer Genome Atlas”
was analyzed across seven tumor types to compare EZH2 expression with known target
genes, commonly silenced in cancer. An inverse correlation between the mRNA levels of
these ﬁve tumor suppressor genes and EZH2 is most apparent in cancers of the prostate,
lung, stomach, and liver, but less so in pancreatic and breast cancer.
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analysis of the results, it has been estimated that of the 70% of DNA ac-
tively transcribed, only 1.2% of the human genome codes for proteins
[138]. Further analysis revealed an abundance of long non-protein-cod-
ing antisense transcripts [139]. lncRNAs are 200 or more nucleotides
long and are transcribed either from intronic sequences, intergenic re-
gions, or from theopposite strand of theprotein-coding gene, producing
antisense transcripts. Due to their size, they have a propensity to form
secondary and higher-order structures [140]. The architecture of the
lncRNA is inextricably linked to its function. For example, the proper
folding ofMEG3 lncRNA is key formodulating the p53 tumor suppressor
activity [141]. Moreover, lncRNAs may alter their structure and adopt
different stable conformations, which allows them to regulate multiple
processes, interacting with DNA, RNAs, and proteins [140]. It is thus not
surprising that they might play an important role in cancer, affecting
most of the recognized hallmarks of the disease [137].
With respect to the regulation of TSGs, aberrant increases of lncRNA
levels may impact TSG transcription through multiple mechanisms
[144]. The lncRNAs can form RNA–protein complexes with DNMT3a
[145], PRC2 [146] and H3K9 methyltransferases [147], and recruit
these complexes to speciﬁc sites, enabling transcriptional repression.
This is achieved by newly synthetized lncRNAs tethering repressive
complexes, thus enabling in cis silencing of genes in the vicinity of the
lncRNA transcription site. Alternatively, lncRNA transcripts can leave
their transcription sites and bind to other RNAs or proteins and guide
them to various genomic locations, thus facilitating the transcriptional
repression in trans [142,148]. In addition to recruiting specialized com-
plexes to the chromatin, lncRNAs also act as decoys for miRNAs thereby
attenuating their ability to silence the transcript targets [144]. One of
the strengths of the idea that aberrant activation of lncRNAs represses
tumor suppressor genes is that their capacity to act in trans [142,143]
would enable them to concurrently silence TSGs that are often seen
co-silenced in cancers (for a list of target genes, see Table 3).
Remodeling the epigenomeplays a crucial role in tumorigenesis [149].
Strikingly, it has been shown through RIP-ChIP assays that at least 38% of
lncRNAs associate with chromatin remodeling complexes, and approxi-
mately 20% bind to PRC2 [148]. Polycomb complexes may repress chro-
matin via two distinct mechanisms: ﬁrst, through trimethylation of
H3K27 and monoubiquitination of histone H2A. The lncRNAs guide and
tether the polycomb repressive complexes (PRC1/2) to speciﬁc genomic
regions for epigenetic silencing [150]. This interaction, in particular, mayTable 3
Long non-coding RNAs and their targets.
lncRNA Tumor suppressor Mechanism of action
ANRASSF1 RASSF1A PRC2 recruitment via SUZ12 and a
ANRIL CDKN2B
miR-99a/miR-449a
PRC2 recruitment via SUZ12 and a
CDKN2A PRC1 recruitment via CBX7 and ad
GAS5 GAS5 Apoptosis
H19 H19 Control of imprinted genes
HOTAIR Altered methylation and gene expression Interacts with PRC2 and LSD1 rep
Linc-p21 TP53 signaling Binds to hnRNP-K, localizing it to
MEG3 TP53 Not determined, may be via direc
PTENP1 PTEN Decoy for the miRNA-mediated si
TARID TCF21 Directs demethylation and activat
XIST XIST Gene silencing, loss may result inhave important implication in the tumorigenic process. This concept is ex-
panded upon below, with additional examples illustrating critical
lncRNA–chromatin interactions and their relevance to cancer.
Some of the most commonly silenced TSGs in cancer are targeted
and repressed by lncRNAs. ANRIL, an antisense non-coding RNA tran-
scribed from the INK4 locus, is a well-characterized lncRNA that binds
to SUZ12 and recruits the PRC2 complex in cis to the CDKN2A and
CDKN2B genes transcribed from this locus, which in turn methylates
H3K27 resulting in gene repression [151,152]. Likewise, depletion of
ANRIL increases expression of the CDKN2B gene and decreases cell pro-
liferation [151]. Precisely which polycomb subunit binds ANRIL is dis-
puted. With one study showing interaction with the SUZ12 subunit of
PRC2 [151], while a second study indicates ANRIL recruits polycomb
through interaction with the CBX7 subunit of PRC1 [152]. It is likely
that non-coding RNAs may in fact target multiple subunits of the
PRC1/2 complexes [153], but most studies indicate an interaction with
PRC2 members [148].
A recent study indicates that expression of ANRIL is elevated in the
non-small cell lung cancer (NSCLC) and is associated with a poor prog-
nosis of the overall survival [154]. A more global approach using
genome-wide association studies (GWAS) shows that ANRIL is among
the susceptibility loci for breast cancer and glioma [155,156]. While
the mechanisms for these clinical studies were not deﬁned, it is likely
mediated, at least in part, through aberrant recruitment of repressive
epigenetic marks.
In a similar manner to ANRIL, an intronic lncRNA called ANRASSF1,
expressed in the RASSF1 tumor suppressor gene locus, recruits SUZ12,
which, in turn, increases the H3K27me3 level at the promoter region
of RASSF1A isoform [126]. This lncRNA promotes cell proliferation
in vitro and is highly expressed in breast tumors, as well as breast and
prostate cancer cell lines [126,157].
It is also proposed that ANRIL down-regulatesmiR-99a/miR-449a via
PRC2, speciﬁcally through SUZ12 binding and H3K27 trimethylation of
the miR-99a/miR-449a promoters [158]. These miRNAs are putative
tumor suppressors that keep cell proliferation and cell cycle progression
in check via repression of the mTOR and CDK6/E2F1 pathways [158]. In
the same study, authors show that the knockdown of ANRIL reduces
gastric cancer cells proliferation in vivo, thereby suggesting its impor-
tant role in tumorigenesis. The above examples highlight the ability of
lncRNAs to methylate DNA via recruiting PRC2 either in cis or in trans,
as in the case of the silencing of the miR-99a/miR-499a distant loci.Cancer
ddition of H3K27me3 mark Breast
Prostate




Non-small cell lung cancer (NSCLC)





ressor complexes Breast cancer
Metastasis and invasion
the transcription sites of genes to be repressed. Lung cancer
Colorectal caner
Non-melanoma skin cancer
t RNA-protein interactions NSCLC
Pituitary tumor
lencing Unknown
ion of tumor suppressor Head and neck
genomic instability Hematologic malignancies
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are attributed to their interactions with the PcG, there is evidence that
at least one of the lncRNAs, HOTAIR, also binds to the lysine-speciﬁc
demethylase 1 (LSD1) thus recruiting the LSD1/CoREST/REST together
with PRC2. In this manner, HOTAIR coordinates gene silencing by scaf-
folding both the PRC2 and the LSD1/CoREST/REST and allowing for his-
tone modiﬁcations to take place [153]. There is currently little evidence
that HOTAIR contributes to cancer initiation via this interaction, but we
know that HOTAIR is deregulated in a variety of cancers, its heightened
expression correlates with tumor progression including increased inva-
siveness [159], metastasis [143], and proliferation [160]. Not all lncRNAs
act to repress chromatin. The lncRNAHOTTIPhas been shown to activate
oncogenes in cis at the HOXA cluster through recruitment of theWDR5/
MLL complex [161]. It is reasonable to think that there is selective pres-
sure for cancer cells to aberrantly activate both of these lncRNAs, and it
is an intriguing idea that HOTAIR andHOTTIPmay act in concert to stim-
ulate oncogenic progression.
Finally, there are also instanceswhen the lncRNA can directly bind to
the DNA and act as a silencer. In the case of the dihydrofolate reductase
(DHFR), the gene has alternative promoters, and the transcript of the
minor upstream promoter maintains transcriptional repression of the
major promoter of DHFR, thus down-regulating its gene expression in
quiescent cells [162]. Key questions regarding the role in lncRNA in
the epigenetic silencing of TSGs still persist. Do lncRNAs reprogram
the epigenetic landscape of gene promoters beyond H3K27me3? Do
they promote subsequent DNAmethylation? There is also scant clinical
evidence of correlations between lncRNA expression and the epigenetic
silencing of TSGs in human tumors. Since lncRNAs appear to promote
late-stage oncogenic events, can they account for the epigenetic silenc-
ing of tumor suppressors apparent in early neoplastic lesions? Future
work will hopefully shed light on these provocative questions.
7. Clinical potential
The reversible nature of epigenetic modiﬁcations makes them at-
tractive anti-cancer therapeutic targets. Reactivation of epigenetically
silenced TSGs presents a challenging goal because of the complexity of
events initiating and maintaining the silenced state. Decades of work
aimed at understanding the basic mechanisms associated with epige-
netic process and their deregulation in cancer have now yielded a boun-
ty of pharmacologic agents capable of restoring the expression of
silenced genes, or shutting down oncogenes. Currently, a spectrum of
epigenetic drugs are in clinical trials including histone deacetylaseFig. 3. Overview outlining the epigenetic action of epigenetic therapies aimed at restoring the
reprogram the epigenetic code to a more physiological state. The impact of EZH2 inhibitors oninhibitors, histone demethylase inhibitors, DNA methyltransferase in-
hibitors, and bromodomain inhibitors. Here we will discuss nucleoside
analogs, EZH2 inhibitors, and HDAC inhibitors, therapies targeting the
processes described above, with the goal of re-expressing silenced
TSGs (Fig. 3). The ﬁrst of this class of inhibitors to be developed, and
most broadly tested in clinical trials, are the DNA methyltransferase
inhibitors.
7.1. Nucleoside analogs
The most clinically relevant DNMT inhibitors developed to date are
cytidine analogs that incorporate into DNA, thereby blocking the cata-
lytic actions of DNMTs, but also triggering their degradation [163]. 5-
aza-2′-deoxycytidine, or decitabine, is a nucleoside analog currently
being tested in over 70 active clinical trials. The outcome of exposure
to decitabine includes reversal of abnormal promoter DNAmethylation,
and repressive histone modiﬁcation leading to the re-expression of si-
lenced genes, including tumor suppressors, and changes in cancer sig-
naling pathways like apoptosis, cell cycle, or stem cell self-renewal
[164–166]. Notably, two recent reports indicate the primary antiprolif-
erative effect of nucleoside analogs is through activation of an anti-
viral response mediated by transcription of endogenous repetitive ele-
ments [167,168]. These data are consistent with many preclinical stud-
ies demonstrating nucleoside analogs potentiate an active immune
response [169–172]. These ﬁndings lead to the emerging possibility of
using epigenetic therapy to prime patients with solid tumors to immu-
notherapy, and clinical trials are underway to test this concept in NSCLC
(NCT01928576).
Decitabine has a favorable toxicity proﬁle [173] and, thus far, is FDA-
approved for the treatment of myelodysplastic syndromes (MDS) and
chronic myelomonocytic leukemia (CMML). Decitabine has proven to
increase survival in responsive patients with high-riskMDS, but the du-
ration of the response is temporary and only 40–50% of patients
responded [174,175]. New nucleoside analogs such as zebularine have
a reduced toxicity proﬁle, and greater bioavailability, which may allow
a broadened use of this drug [176]. While myelosuppression may be a
clinically important goal for reducing cancer stem cells of the bonemar-
row, myelosuppression leads to increased susceptibility to infection.
This severe toxicity may limit the utility of this class of compounds
[177].
In theory, reactivating tumor suppressor genes is a logical means to
ablate the uncontrolled proliferative and survival capacity of cancer
cells. Why are nucleoside analogs not more effective clinically? Modernexpression of TSGs. Nucleoside analogs have been proven to reactivate TSGs and partially
epigenetic modiﬁcation beyond H3K27me3 is awaiting clariﬁcation.
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Currently, there is a shift toward personalized cancer therapy, where
speciﬁc pathological subtypes are targeted with precision drugs. The
lack of suchmolecular biomarkers to predict response to nucleoside an-
alogs may help explain why agents such as decitabine have had limited
clinical impact on cancers beyond MDS/CMML. Further, recent reports
showing DNMT inhibition activates not only the transcription of
tumor suppressor genes but also LINE and SINE repetitive elements
highlight the non-speciﬁc nature of these agents [167,168]. It possible
that an unwanted effect of nucleoside analogs is the activation of epige-
netically silenced oncogenes or pluripotency genes that might limit
their anti-cancer potential [178–180].
A new generation of DNMT inhibitors (non-nucleoside agents) have
been developed with the hope of improving drug potency, and speciﬁc-
ity due to their higher selectivity [181,182]. Speciﬁc DNMT inhibitors
might also be amenable to discovery of predictive biomarkers. Each
DNMT isoform may be overexpressed in particular types of cancer. For
example, overexpression of DNMT3b is common in acute myeloid leu-
kemia [183] and breast cancer [34], while DNMT3a levels remain stable.
Non-nucleoside agents targeting a speciﬁc isoform might address the
issue of “over-targeting.”
Intriguingly, IDH1/2 mutations may act as a novel biomarker to pre-
dict the efﬁcacy of nucleoside analogs. IDH1/2 mutations are frequent
events in a number of difﬁcult to treat cancers including glioma and
cholangiocarcinoma. IDH1/2 mutations result in an altered enzymatic
activity leading to the production of the onco-metabolite 2-
hydroxyglutarate (2HG) [184]. 2HG acts as a competitive inhibitor of
α-ketoglutarate-dependent dioxygenases. A number of such enzymes
help shape the epigenome, speciﬁcally, through demethylation of both
target histones and DNA. An important recent study showed that IDH
mutation leads to an aberrant increase inDNAmethylation at chromatin
boundaries, due to the inactivation of TET-mediated DNA demethyla-
tion [185]. Such DNA methylation was prohibitive to CTCF binding,
allowing activation of oncogene transcription through aberrant enhanc-
er promoter contacts. Exposure to 5-azacytidine restored CTCF binding
and abrogated the expression of the oncogenic driver, PDGFRA. Of
course, further work needs to be done to deﬁne whether disruption of
key insulator elements truly predicts sensitivity to nucleoside analogs,
or combination therapies with this class of drugs. But this work under-
scores the importance of uncovering molecular biomarkers to deﬁne
subsets of tumors that will respond to epigenetic therapies.
7.2. EZH2 inhibitors
As outlined above, EZH2 represents an attractive target for chemical
inhibition due to its role in silencing, overexpression and mutation in
cancer. S-adenosyl-L-methionine (SAM) is considered the universal
methyl donor for catalytic reactions of histone methyltransferases
(HMTs). To date, clinically relevant inhibitors of EZH are all SAM-
competitive small molecules.
EPZ 6438 and GSK 2816126 are considered pharmacologically im-
proved EZH2 inhibitors with low nanomolar range afﬁnity and a higher
selectivity for EZH2 than previously described inhibitors [186,187]. Both
of these small molecules are being tested in Phase I clinical trials against
hematopoietic malignancies. Because all HMTs require SAM for enzy-
matic activity, the likelihood for off-target effects might be high, but
this barrier is seemingly one that can be chemically overcome. For ex-
ample, EZH1, which is 96% identical to EZH2 within the SET domain is
inhibited signiﬁcantly less than EZH2 by GSK 126 (an analog of GSK
2816126), as are 20 other HMTs [186]. Thus, EZH2 inhibitors display a
degree of speciﬁcity currently lacking in nucleoside analogs. Currently,
we are still awaiting the results of clinical trials to provide a clearer pic-
ture of their toxicity proﬁle.
Both EPZ 6438 and GSK 126 exhibit cytotoxic and antiproliferative
effects on DLBCL cells harboring EZH2 mutations, and decidedly inhibit
the growth of EZH2 mutant DLBCL xenografts in mice, albeit at fairlyhigh concentrations (50–80mg/kg or greater) [186,187]. In contrast, xe-
nografts with wild-type EZH2 were affected in a limited fashion. It
should be noted that in vitro, 50% growth inhibition was generally not
reached until a week, or longer, of exposure to EZH2 inhibitors in
these same studies. Is such a delay in growth suppression under the
ideal conditions of tissue culture a cause to doubt the clinical outcomes
of these patient trials? These data also call into question the speciﬁcity
of the drugs. It would be interesting to compare the antiproliferative ef-
fects of these drugs to those observed upon EZH2 knockdown. Mecha-
nistically, the target genes of EZH2 inhibitors, whose repression
stimulate a cytotoxic response, are still not well-deﬁned. GSK 126 is
known to activate a distinct set of immune-related genes, but it is un-
clear if these mediate the antiproliferative effects, or even if the pro-
moters of these genes were enriched for H3K27me3 prior to drug
exposure [186]. Thus, more work needs to be done to deﬁne the precise
molecular mechanisms whereby these inhibitors carry out their anti-
tumor effects.
Catalytically activatingmutations of EZH2 provide ameaningful bio-
marker for EZH2 inhibitor sensitivity that is sorelymissingwith nucleo-
side analogs. Recent evidence suggests that EZH2 has oncogenic activity
beyond its catalytic domain [188], supporting the idea that next-gener-
ation EZH2 inhibitors might focus on dismantling the PRC2 complex. As
we now know, silenced tumor suppressors are characterized by a num-
ber of changes to the epigenome. Thus, targeting multiple pathways
that contribute to silencing might be a more powerful approach to epi-
genetic therapies. Not surprisingly, many preclinical studies show pro-
found synergy between epigenetic drugs [189–191], and we suggest
that such combinations likely represent the most potent approach to
epigenetic therapy.
7.3. Histone deacetylase inhibitors
Lysine acetylation is a covalent post-translational modiﬁcation me-
diated by lysine acetyltransferases (KATs). Historically, the ﬁrst acety-
lated proteins to be identiﬁed were histones, but since that time
hundreds of other acetylated proteins have been identiﬁed [192]. Lysine
acetylation is a reversible modiﬁcation mediated by four classes of ly-
sine deactylases (KDACs). While both KAT and KDAC activities are pre-
dominantly nuclear, it is now widely accepted that lysine acetylation
and its removal is an important protein regulatory mechanism within
the cytoplasmic compartment aswell [193,194]. Pharmacological inhib-
itors of KDAC activity (KDACi) have been extensively tested in clinical
trials and overall, the favorable responses have been more pronounced
against hematopoietic malignancies than solid tumors. An exciting ad-
vance in thisﬁeld is theﬁnding that patientswith several hematopoietic
malignancies, including cutaneous T-cell lymphoma (CTCL) and multi-
ple myeloma show signiﬁcant clinical responses to this class of drugs.
The pan-KDAC inhibitors vorinostat and romidepsin are now FDA ap-
proved for the treatment of relapsed or refractory cutaneous T-cell lym-
phoma (CTCL). Recently, pabobinostat, another pan-KDAC inhibitor,
was FDA approved for the treatment of progressive multiple myeloma.
Certainly, a factor in their FDA approvalwas their favorable toxicity pro-
ﬁle. As monotherapy, the primary KDACi toxicities include thrombocy-
topenia and fatigue, with stronger toxicities including severe
thrombocytopenia, or myelosuppression, becoming more apparent
when used as combination therapies [195]. In comparison to
pabobinostat, vorinostat appears to have a milder toxicity proﬁle
[195]. To better understand the anti-tumor activity of these drugs, we
should ﬁrst examine the cellular roles of protein acetylation.
Histone acetylation was the ﬁrst lysine acetylation event identiﬁed,
and its functional relevance to the transcriptional process has been
broadly studied. Even though histone acetylation was ﬁrst described
over 50 years ago [196], there is still much to learn regarding the varied
effects of this covalent post-translational modiﬁcation on chromatin
structure and transcription. Histone acetylation is enriched in transcrip-
tionally active regions of the genome, especially at proximal promoters
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on at least two levels to facilitate the binding of transcription factors.
First, there is biochemical evidence that N-terminal acetylation loosens
contact between core nucleosome proteins and DNA, thereby making
transcription factor binding sites more accessible [197,198]. Likely hav-
ing a greater inﬂuence on transcriptional outcomes is the recruitment of
bromodomain proteins. Bromodomain proteins recognize acetylated
histones and are actively recruited to enhancer and promoter regions
[199]. Bromodomain proteins have diverse functional properties
allowing them to modulate transcriptional activity. SMARCA2/4 for ex-
ample, harbor ATPase chromatin remodeling activity, allowing them to
shift or displace nucleosomes, generating DNAse I hypersensitive sites
conductive to transcription factor binding [200]. Other bromodomain
proteins, such as Brd4, act to enhance transcriptional elongation
through Serine 2 phosphorylation of the Pol II C-terminal domain
[201]. Still others, such as TAF1, may act to directly recruit Pol II to pro-
moters [202].
Based on the role of acetylation in promoting transcription, it is not
surprising that targeting KDACs to reporter genes leads to a reversible
shutdown of transcription, associated with loss of histone acetylation
[41]. Thus, it is a reasonable hypothesis that disruption of this pathway
might lead to epigenetic silencing of TSGs. As described above, epigenet-
ic silencing of TSGs is associatedwith a number of epigenetic events, but
it is uncertain that local KDAC activity leads to further epigenetic alter-
ations commonly seen at silenced cancer loci, beyond histone
deacetylation. Additionally, there are few reports indicating that dereg-
ulation of KDAC activity in cancer cells initiates irreversible epigenetic
silencing, and overall it seems unlikely that aberrant KDAC activity
leads to TSG silencing in cancer. In contrast to a role for initiation of
TSG silencing, restoring histone acetylation through pharmacologic in-
hibition of KDAC clearly reactivates the expression of a subset of si-
lenced TSGs including the classic TSGs CDKN2AARF or SFRP-1 [203,204].
KDACi also act in synergy with DNA methylation inhibitors to restore
the expression of TSGs showing highly methylated promoters, indicat-
ing a role for KDACs in the maintenance of gene silencing. It is through
the reactivation of silenced TSGs that KDACi are generally thought to
exert their anti-cancer activity. A closer examination of the studies
using KDACi to restore gene expression provides valuable insights into
both the biology of KDACs, the therapeutic potential of KDAC inhibitors,
while raising new questions concerning their mode of action.
TSGs having promoter methylation are generally regarded as being
irreversibly silenced. There are numerous reports indicating that
KDACi are unable to reactivate methylated TSGs, especially when drug
exposure is limited to a 24 hr exposure [205–207]. However, longer ex-
posures do lead to reactivation of methylated genes, but this effect may
not be direct. Long exposures to KDACi suppress the expression of
DNMT1 and DNMT3b, resulting in genome-wide hypomethylation
[208,209]. Thus, it is entirely possible that reactivation of silenced
TSGs by KDAC inhibitors is a direct consequence of the loss of these
two critical DNMTs. This concept is controversial, and recent reports in-
dicate KDACi may indeed restore epigenetically silenced TSGs, albeit
transiently, without altering DNA methylation proﬁles [204,210]. Fur-
ther work will be required to decipher the precise epigenetic landscape
of endogenous, silenced, TSGs that is conducive to reactivation by KDAC
inhibition.
Beyond DNA methylation, histone acetylation has a complex rela-
tionship with other histone modiﬁcations. For example, KDACi cause
widespread histone hyperacetylation as expected, but secondary
changes to the post-translational modiﬁcation proﬁle of histones can
also be observed. For example, a global increase in both the transcrip-
tional activating mark, H3K4me3 is observed after exposure to KDACi
[211]. In stark contrast, the EZH2-directed repressive mark H3K27me3
accumulates at proximal promoter regions across the genome even
after exposures of just 1 hr to clinically relevant KDACi [212]. These
seemingly paradoxical epigenetic changes make it challenging to pre-
dict whether KDACi should have a stronger inﬂuence on transcriptionalactivation or repression. In light of these complex epigenetic changes
imparted by KDACi, it might come as no surprise that transcriptome
proﬁling reveals a nearly equivalent number of genes down-regulated
by KDACi as those up-regulated [213,214]. Notably, in CTCL, where
KDACi are FDA approved as a therapeutic intervention, exposure to
the KDAC panobinostat led to a striking decrease in gene expression
proﬁles, with comparatively fewer genes being up-regulated [215].
To date, biomarkers to predict patient cohorts that will respond to
KDACi are lacking in both CTCL and myeloma. Considering that the re-
sponse rate to CTCL is less than 35%, biomarkers seem critical to identify
the responsive cohort [216]. Such predictive biomarkers may also help
expand the treatable population beyond CTCL and myeloma and may
facilitate the identiﬁcation of complimentary pathways that may be
targeted in synergy with KDACi. Perhaps looking at the other activities
of KATs (and by association KDACs) beyond the regulation of transcrip-
tionmight provide insights into the anti-cancer properties of KDACi and
facilitate the discovery of new biomarkers.
A global survey of proteins losing acetylation after exposure to a
broad range of KDACs using mass spectrometry predicted between
20% and 60% of proteins acted upon by KDACi were localized in the cy-
toplasm [217]. Consistent with this, recent work has greatly expanded
the role of KATs beyond modulation of transcription. In the nucleus,
this includes a critical role in response to damaged DNA [218]. In the cy-
toplasm, acetylation of mitochondrial proteins regulates respiration
[219], and protein acetylation plays key roles in autophagy and organi-
zation of the cytoskeleton [194]. Importantly, there is evidence that
some of these non-transcriptional processes, such as autophagy, may
dictate cell sensitivity to KDACi [220,221].
In sum, it is clear that KDACi have great clinical potential, and there
are opportunities for improvement. First, we must stop thinking of
KDACi asmerely transcriptional regulators. Wemust broaden our stud-
ies to examine their impact on other processesmodulating proliferation
and survival. Such studies will help reveal the critical pathways modu-
lated by KDAC inhibition thatmediate its anti-cancer properties thereby
expediting the discovery of predictive biomarkers for this class of
compounds.8. Future perspectives and alternatives
Amajor goal of future researchwill be to decipher how the extracel-
lular environment, and oncogenic events in the cytoplasm, communi-
cate to the nucleus, to rearrange normal epigenetic programming. For
example, how does RTKmutation lead to speciﬁc DNAmethylation pro-
ﬁles? Or, vice versa, do epigenetic alterations facilitate the acquirement
of particular genetic aberration? Beyond genetic drivers of oncogenesis,
it is well-established that a variety of environmental carcinogens confer
reproducible changes to DNAmethylation patterns [222–224]. It will be
worthwhile to investigate whether carcinogens may carry out such
reprogramming, at least in part, through one of theﬁvemechanisms de-
scribed above.
It will also be of interest to determinewhether themechanisms of si-
lencing described within this reviewwork independently of one anoth-
er, or conversely, and more likely in our opinion, multiple silencing
networks act cooperatively to irreversibly shut down transcription.
Studies providing mechanistic insights into how the dysfunction of a
single epigenetic factor leads to reprogramming of a spectrum of epige-
netic marks would also contribute invaluable information to the ﬁeld. It
will also be of great interest to examine whether the activity of TET de-
methylases have an impact on the expression of TSGs.
We are conﬁdent that future studies will indeed answer such gran-
diose questions. The advent of high throughput sequencing technolo-
gies has provided researchers with exciting opportunities to probe
tumors and cell lines for epigenomic reprogramming thereby answer-
ing questions that were previously unattainable. Such high throughput
sequencing capabilities and the introduction of the CRISPR/Cas9 system
285A. Kazanets et al. / Biochimica et Biophysica Acta 1865 (2016) 275–288for genomic editing will undoubtedly allow us to deﬁne mechanisms
whereby tumor suppressor genes are silenced in the coming years.
From a therapeutic perspective, futurework both in the lab and clin-
ic will need to sort out whether targeting epigenetic events non-
speciﬁcally, such as with 5-Aza-2-deoxycytidine, is a less effective ap-
proach than precision medicine targeting epigenetic regulators, such
as BET inhibitors. The future may also hold the promise of editing the
genomewithin tumors in order to restore the expression of tumor sup-
pressor genes, without further alterations to the genome. Overall, it is
clear that basic, biochemical analysis of our epigenome is being translat-
ed into exciting new therapies for multiple diseases.Transparency document
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